Bu Rixin, a partner of Chuangdao Investment Consulting, said in an interview with the science and technology innovation board Journal that the 10 billion M&A fund is mainly aimed at the "integrated circuit design industry", which may be related to the end of the IPO dividend period of chip design companies.In July this year, when Shanghai promoted the establishment of the parent fund of three leading industries with a total scale of 100 billion yuan, it said that it would focus on the three leading industries of integrated circuits, biomedicine and artificial intelligence, and give play to the functions of "investing early and investing small", industrial investment, merger and acquisition integration, and strengthening the chain, so as to improve the overall energy level and development level of the three leading industries in Shanghai.In addition to the integrated circuit design industry, Shanghai will also set up a M&A fund for the biomedical industry with a scale of 10 billion yuan.
Big move! Two billion M&A and restructuring funds in Shanghai have come to target the chip and pharmaceutical industries.Yuan Shuai, the founder of the new productivity meeting room of Xinzhi School, said in an interview with the reporter of science and technology innovation board Daily that the Yangtze River Delta where Shanghai is located is an important place of integrated circuit industry, and the establishment of the 10 billion yuan integrated circuit design industry M&A fund is a strong support for Shanghai's semiconductor design industry.Biomedicine, as one of the leading industries in Shanghai, has a scale of nearly one trillion yuan. In 2023, the industrial scale reached 933.732 billion yuan, an increase of 4.9%; Shanghai's biomedical industry chain is relatively complete, with many medical device enterprises and CRO, CMO and CSO enterprises. Therefore, Yuan Shuai believes that the Shanghai Municipal Government will set up a 10 billion yuan M&A fund for biomedical industry, which is expected to cultivate internationally competitive biomedical enterprises through mergers and acquisitions.
Bu Rixin said that only through mergers and acquisitions and accelerating industrial integration can the benign development of the industry be promoted, which is also one of the most effective measures.Among them, Chengdu Ruiyuan Semiconductor is mainly engaged in the research and development, design, packaging and sales of power management chips, and one of its main products is DC/DC chips. A-share listed companies include Jingfeng Mingyuan, Fumanwei, Shanghai Beiling and Xidiwei, all of which have certain market share and competitiveness in the DC/DC chip market.Bu Rixin said that only through mergers and acquisitions and accelerating industrial integration can the benign development of the industry be promoted, which is also one of the most effective measures.